Redeye provides a research update following Egetis' Q4 report and recent events.
Redeye comments on the news that Egetis has completed its rolling NDA submission for Emcitate in the US.
Redeye gives a short comment on the news that a bill has been passed in the US House of Representatives regarding the rare pediatric priorit...
Redeye returns with an updated view of Egetis Therapeutics following the Q3 report and the recent ReTRIACt readout.
Redeye gives an initial comment on the top-line readout from the ReTRIACt study with Emcitate.
Redeye has a positive take on the news that Egetis has been granted a rolling NDA review based on currently available clinical data, and tha...
Redeye comments on the news that Egetis has secured an agreement for Emcitate in the Gulf region.
Redeye endorses the news that Egetis has secured cSEK183m in a directed issue and give our initial take.
Egetis has rapidly transferred all but one German patient, supporting the launch and indicating positive acceptance of Emcitate at a favorab...
Egetis has launched Emcitate in Germany. The progress made in the US include advancing the US study and securing a Breakthrough Therapy Desi...
Tiratricol now has US FDA Breakthrough Therapy Designation for MCT8 deficiency, which is essential for several important reasons.
Egetis delivered sales along expectations with reasonable cost control, and more importantly, the German launch is underway following the Eu...
Egetis delivered sales along expectations and more importantly, the German launch is underway following the European approval in February, s...
Redeye returns with an updated view of Egetis Therapeutics following the Q4 report and the recent approval in the EU.
Redeye endorses today’s news that the European Commission has approved Emcitate for “the treatment of peripheral thyrotoxicosis in patients ...
Redeye comments on Egetis investor day yesterday, that focused on the commercialization of Emcitate and some long-term objectives.
Redeye comments on the positive news that Emcitate has received a positive CHMP opinion for MCT8 deficiency – and is close to commercializat...
Redeye comments on the news that Egetis has decided to explore RTH-beta as the next indiction for tiratricol/Emcitate.
Redeye returns with an updated view of Egetis Therapeutics following the Q3 report and recent events in the company.
Redeye endorses the news that Egetis has finalized a directed issue of some SEK300m to new and existing shareholders, including to internati...
Redeye returns with an updated view of Egetis Therapeutics following the Q2 report and recent events in the company.
Redeye is optimistic about today’s news from Egetis Therapeutics that patients on Emcitate are associated with survival benefits compared to...
Redeye endorses today’s news that the ETA (“European Thyroid Association”) recommends Emcitate as a long-term treatment for MCT8 deficiency ...
Redeye comments on the news that the company’s complementary clinical study TRIAC II, which focused on neurocognition in young MTC8 patients...
Redeye endorses today’s news that Egetis has received a “Promising Innovative Medicine (PIM) designation” in the UK, which is a first step t...
Redeye updates its view of Egetis following the Q1 report and recent events in the company.
Redeye notes that Egetis’ Q1 report presented SEK12.
Redeye updates its view of Egetis following the Q4 report and recent events in the company.
Egetis’ Q4 report presented SEK32.6m in revenues, of which SEK14.
Watch the replay of Egetis Therapeutics' capital markets day.
Redeye gives its initial comments on yesterday's investor day, which gave a broad overview of the company's plans related to Emcitate.
This Tuesday, between 15:00-18:00, Egetis Therapeutics hosts a Capital Markets Day.
Redeye endorses the news that the company’s disease awareness activities have resulted in an additional 50 patients being diagnosed with MCT...
Redeye provides an additional comment on the recent news that Egetis has outlicensed the rights to Emcitate in Japan to Fujimoto.
Redeye endorses today’s news that Egetis has outlicensed the rights to Emcitate in Japan to Fujimoto.
Redeye updates its view of Egetis following the Q3 report and recent events in the company.
Stabil finansiell position Egetis rapport för det tredje kvartalet innehöll inga överraskningar.
Redeye notes that Egetis’ Q3 report presented SEK12.
Reser betydande kapital Egetis meddelade under tisdagskvällen att de reser 462 mkr, varav 172 mkr genom en riktad emission och 290 mkr i sku...
Redeye provides an additional comment on the news that Egetis Therapeutics has secured in total SEK462m in funding, including SEK172m from a...
Redeye is encouraged by the recent announcement from Egetis Therapeutics that it has secured a total of SEK462m through a combined private p...
Redeye endorses today’s news that Egetis has filed a marketing authorization application (“MAA”) for Emcitate, targeting MCT8 deficiency, to...
Inga överraskningar i rapporten Egetis rapport för det andra kvartalet var i linje med våra förväntningar.
Redeye updates its view of Egetis the Q2 report and recent events in the company.
Försening i tidslinjen... Egetis meddelade under onsdagskvällen att de förskjuter den planerade tidslinjen mot ett marknadsgodkännande för d...
We update our base case to reflect the new timelines for the US submission and Aladote.
Redeye notes that the first hospital in the US trial with Emcitate (ReTRIACt) has been activated and that the study duration and timeline fo...
Redeye has a neutral take on the announcement that the discussions of a potential acquisition of Egetis have been terminated, as the offer a...
Inga överraskningar Egetis presenterade under onsdagen en Q1-rapport som var i linje med våra förväntningar.
Redeye returns with a research update following the Q1 report.
Yesterday, Egetis acknowledged that it has talks with certain external parties about a possible acquisition of the company, as reported by B...
Rapportkommentar Egetis släppte under onsdagen sin rapport för det fjärde kvartalet.
Redeye returns with a research update following the Q4 report and recent progress in the company.
Redeye notes that Egetis’ Q4 report presented SEK5.
Redeye endorses the news that Egetis Therapeutics has conducted a directed share issue of SEK210m and give our initial take.
Redeye updates its view of Egetis following a change of lead analyst and an eventful year, including a de-risked strategy to market and upco...
Rapportkommentar Egetis presenterade under gårdagen sin Q3-rapport.
Redeye comments on Egetis’ Q3 report and reiterate our view (for now) of the company.
Redeye is encouraged by yesterday’s capital market day, which further emphasized that Egetis has a clear and derisked way to the market with...
Tydlig och riskreducerad väg till marknad I Egetis ser vi ett biotechbolag med en tydlig och riskreducerad väg till marknad.
Redeye leaves a comment on the Q2 report published by Egetis Therapeutics earlier this morning.
Redeye is encouraged by Egetis Therapeutics' announcement earlier this morning, stating that the company has established a US subsidiary as ...
Redeye leaves a comment on the Q1 report from Egetis Therapeutics released earlier this morning.
Redeye leaves a comment following Egetis therapeutics’ announcement earlier this morning of a SEK 180 fully guaranteed preferential rights i...
Redeye is encouraged by Egetis Therapeutic’s announcement earlier today, stating that the FDA has granted Orphan Drug Designation (ODD) to E...
Redeye leaves a comment on the Q4 report from Egetis Therapeutics released earlier this morning.
Redeye believes the Q2 report supports our view that flagship project Emcitate is on track.
